In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in...

Full description

Bibliographic Details
Main Authors: M. Martinez-Lage, R. Torres-Ruiz, P. Puig-Serra, P. Moreno-Gaona, M. C. Martin, F. J. Moya, O. Quintana-Bustamante, S. Garcia-Silva, A. M. Carcaboso, P. Petazzi, C. Bueno, J. Mora, H. Peinado, J. C. Segovia, P. Menendez, S. Rodriguez-Perales
Format: Article
Language:English
Published: Nature Publishing Group 2020-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-18875-x

Internet

https://doi.org/10.1038/s41467-020-18875-x

Similar Items